Montelukast
- Generic Name
- Montelukast
- Brand Names
- Singulair
- Drug Type
- Small Molecule
- Chemical Formula
- C35H36ClNO3S
- CAS Number
- 158966-92-8
- Unique Ingredient Identifier
- MHM278SD3E
- Background
Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs. Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticos...
- Indication
Montelukast is indicated for:
...
- Associated Conditions
- Asthma, Exercise-Induced Bronchospasm, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
- Associated Therapies
- -
Time-Effect of Montelukast Protection
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2009-07-09
- Lead Sponsor
- Universita di Verona
- Target Recruit Count
- 69
- Registration Number
- NCT00935415
- Locations
- 🇮🇹
Pediatric Dept Hospital of Bolzano, Bolzano, Italy
The Effect of Montelukast Treatment in Wheezy Infants
- Conditions
- Interventions
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- University of Helsinki
- Target Recruit Count
- 112
- Registration Number
- NCT00934713
- Locations
- 🇫🇮
Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, P.O.Box 160, Finland
Effect of Montelukast on Remodelling Markers in Asthmatic Children
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Universita di Verona
- Target Recruit Count
- 30
- Registration Number
- NCT00875082
- Locations
- 🇮🇹
Pediatric Department, University of Verona, Verona, Italy
A Study To Assess The Effect Of PF-03893787 On Lung Function Following An Allergen Challenge In Asthmatic Subjects
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2010-01-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00856687
- Locations
- 🇬🇧
Pfizer Investigational Site, Harrow, Middlesex, United Kingdom
Airborne Ultrafine and Fine Particulate Matter: A Cause for Endothelial Dysfunction in Man?
- First Posted Date
- 2008-12-24
- Last Posted Date
- 2009-05-21
- Lead Sponsor
- Marywood University
- Target Recruit Count
- 24
- Registration Number
- NCT00814281
- Locations
- 🇺🇸
Marywood University, Scranton, Pennsylvania, United States
Montelukast in Children With Wheezing
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Universita di Verona
- Target Recruit Count
- 40
- Registration Number
- NCT00775697
- Locations
- 🇮🇹
Clinica Pediatrica Universita' di Verona Policlinico GB Rossi, Verona, Italy
Montelukast Post-marketing Comparative Study With Theophyline Added to Inhaled Corticosteroid (0476-396)
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 84
- Registration Number
- NCT00756418
Investigation to Identify Predictors of Response to a Treatment With Montelukast
- First Posted Date
- 2008-07-24
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- Marien Hospital Wesel
- Target Recruit Count
- 50
- Registration Number
- NCT00721240
- Locations
- 🇩🇪
Marien Hospital Wesel gGmbH, Wesel, NRW, Germany
The Effects of Montelukast on Smokers With Asthma
- Conditions
- Interventions
- First Posted Date
- 2008-07-09
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- Inje University
- Target Recruit Count
- 105
- Registration Number
- NCT00712335
- Locations
- 🇰🇷
Asthma and Allergy Center, Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of
A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years (0476-907)
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 500
- Registration Number
- NCT00700661
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.